billHJRES197Event Thursday, June 18, 2026Analyzed

Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program".

Neutral

Summary

HJRES197 is a procedural resolution of disapproval under the Congressional Review Act targeting a CMS rule on ACA benefit and payment parameters for 2027. It has been introduced and referred to committee with 13 cosponsors, but is in an early stage with no substantive market impact yet.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HJRES197 is a CRA resolution targeting an ACA rule, not a funding bill
  • 2.The bill is in early committee stage with no immediate market impact
  • 3.No specific companies or sectors are affected by this procedural action

Market Implications

No market implications at this stage. The resolution is in early committee referral and has not advanced. Investors should monitor if the bill gains traction in committee or if a companion bill is introduced in the Senate, but currently there is no actionable signal for any ticker.

Full Analysis

This bill is a joint resolution of disapproval under the Congressional Review Act (CRA) aimed at nullifying a rule submitted by the Centers for Medicare & Medicaid Services (CMS) regarding the Patient Protection and Affordable Care Act's Notice of Benefit and Payment Parameters for 2027 and the Basic Health Program. The resolution was introduced in the House on June 18, 2026, and referred to the House Committee on Energy and Commerce. It has 13 cosponsors, all from the Democratic party, led by Rep. Kathy Castor (D-FL-14). At this early stage, the bill has not been marked up or reported out of committee, and no companion bill has been identified in the Senate. The CRA process requires a simple majority in both chambers and presidential signature to nullify a rule, but the resolution is procedural and does not authorize or appropriate any funding. The specific rule being challenged is not detailed in the provided text, but it relates to the ACA's benefit and payment parameters, which typically affect insurance market regulations, not direct federal spending. Given the early stage and procedural nature, there is no near-term market impact on any publicly traded companies. The resolution is unlikely to advance given the current political landscape, as it would require a Democratic majority in both chambers and the President's approval, which is not specified. No real market data is provided, and no companies are directly affected by this procedural action.

Key Legislators

Rep. Castor, Kathy [D-FL-14]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.